Case Report: Trametinib in the treatment of patients with metastatic lung adenocarcinoma harboring NF1 mutation: a case series and literature review
In this small case series, NSCLC patients with <i>NF1</i> alterations did not derive clinical benefit from trametinib. While these data do not support trametinib as a treatment option for <i>NF1</i>-mutated NSCLC, larger studies are required to draw firm conclusions.
Authors
- Maxime Borgeaud (ORCID: https://orcid.org/0000-0003-1262-5641)
- Floryane Kim
- Alfredo Addeo (ORCID: https://orcid.org/0000-0003-0988-0828)
- Petros Tsantoulis (ORCID: https://orcid.org/0000-0003-3613-6682)
- Claudio De Vito (ORCID: https://orcid.org/0000-0002-4966-1278)
Institutions
- University Hospital of Geneva (CH)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-10-15
- DOI
- https://doi.org/10.3389/fonc.2025.1481284
- Primary Topic
- Neurofibromatosis and Schwannoma Cases
- Type
- article
- Field-Weighted Citation Impact
- 0.00